Pharma group builds out American supply chains as part of preparations for potential US tariffs
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019
The first in an FT series looking at the new energy behind the fight for cancer cures
German healthcare group buys business that specialises in producing radioactive chemicals used in scans
Extreme shortages of actinium are holding up the promising field of radiopharmaceuticals
Swiss drugmaker says it will only sell medication privately if health systems cannot pay
Group of 11 pharma, tech and luxury shares echoes US dominance of ‘Magnificent Seven’
Key drugs are due to lose exclusivity in the important US market in 2027
Sector has been critical of government after sharp rise in clawback tax
Swiss drugmaker’s generic business could have market capitalisation of $18bn-$25bn
Pharma industry deprioritising certain pills with shorter exclusivity period, says head of Swiss drugmaker
Swiss drugmaker says potential deals not attractive enough to pursue
Vas Narasimhan warns giving Brussels power over drug manufacturing during crises will hit investment
Swiss group rethinks NHS collaboration after low take-up of treatment during rollout via GPs
Technology has the potential to forge closer relationships between law firms and clients
Swiss group takes bold step to focus on faster-growing and higher-margin medicines
Chief executive says changes will make Swiss drugmaker ‘more agile and competitive’
The Swiss company’s chief executive has to decide on the future of its $10bn generics business
Potential suitors include Blackstone and Carlyle but no formal bids have been made
Selling off its Sandoz unit could help stave off an attack by activists
Blackstone, Carlyle and EQT among those interested in bidding for drug manufacturer Sandoz
Swiss drugmaker to license antiviral therapeutic after success in early-stage tests
Twenty-year shareholding had kept the two Swiss drugmakers closely linked
‘Pure pharma’ companies were the minority a decade ago but are now back in fashion
Unit accounts for a fifth of group sales and could be spun off
